Translating Discovery to Impact
Interview with Pedro Henrique Quintela: GNA NOW
The Gram-Negative Antibacterials NOW (GNA NOW) project aims to develop novel compounds with new modes of action. The consortium of 11 partners leverages support from a network of platforms with key expertise in the research and development of antibiotics, which is required for a new molecular entity to progress from lead or pre-candidate/candidate stages to Phase I completion. One of the GNA NOW researchers, Pedro Henrique Quintela, shared his perspective on the global AMR issue and the efforts needed to address it.
What is your role in the fight against AMR?
I work on finding new therapeutics for enteric bacterial infections in the context of in vivo efficacy models development. My research has the potential to provide valuable in vivo proof-of-concept data for new molecules that can hopefully help to advance the treatment of challenging and high-burden infectious diseases. We need models that are more translatable to clinical settings and that address a broader range of pathogens highly relevant to Global Health.
“One of the most rewarding aspects of my work is the anticipation that comes with testing new molecules, knowing that each experiment could help bring us closer to meaningful breakthroughs.”
Pedro Henrique Quintela is an Investigator at GSK Global Health R&D Medicines, Madrid, Spain.
What brought you to the AMR research?
I graduated in Pharmacy, where I was quickly introduced to the concept of antimicrobial resistance and its profound impact on global health. Since then, bacterial diseases have always fascinated me because of the complex interactions between the host and different pathogens. This interest led me to pursue a PhD in Medical Microbiology and ultimately a career dedicated to tackling AMR.
What trends in AMR research are you most excited about?
I am pretty excited about the deeper understanding of bacterial pathogenesis and host-pathogen interactions that has been generated. Alongside advancements in artificial intelligence and its impact on drug discovery and data analysis, I hope we will soon see novel mechanisms for fighting bacteria.
Interdisciplinary collaboration is absolutely essential for bringing solutions to major challenges like AMR. As an example, in the GNA NOW consortium, we have experts from different fields, including advanced in vitro systems, animal models, clinical microbiology and pharmacokinetic modelling. Together, we can build a more translational and impactful project that bridges preclinical research and clinical applications.
What do you believe is the most important message for the public to understand about AMR?
The most important message for the public to understand about AMR is that it’s a global health threat that affects everyone – not just future generations, but people today.
AMR disproportionately impacts people in lower-income countries, particularly those in sub-Saharan Africa and Asia. Tackling it requires urgent, collective action, from responsible use of antibiotics to sustained investment in innovation.
The public plays a vital role in the fight against AMR. Responsible use of antibiotics, for instance, can help reduce the risk of resistance. Practising good hygiene and staying informed about AMR can also help contribute to prevention efforts.
What advice would you give other researchers or students interested in AMR research?
My best advice for those interested in AMR research is to seek out and collaborate with experts in the field that aligns with your passion. In addition, it is important to be open-minded about innovative approaches that can be applied to your research.
What helps you to stay motivated about your work?
I focus on the excitement of discovery and the potential impact of my research. I love generating new data and finding novel solutions for my research project. One of the most rewarding aspects of my work is the anticipation that comes with testing new molecules, knowing that each experiment could help bring us closer to meaningful breakthroughs.
How do you balance your professional and personal life?
When I’m not at work, I make it a priority to spend quality time with my family and engage in hobbies that help me disconnect and recharge. I also ensure I get proper rest, as it’s essential for maintaining focus and energy when returning to work.
I love all about music and sports (both playing and watching). I also enjoy spending time with my son, especially our visits to the park, which provide a wonderful opportunity to connect.
Register for the GNA NOW webinar on 9 December 2025 to hear more about the standardisation of in vitro evaluation systems.
Want to know more? Take a look at the publications from GNA NOW:
- Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9. Green Open Access available through DiVA.
-
Pantel L, Guérin F, Serri M, et al. Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species. Antimicrobial Agents and Chemotherapy. 2022;66(11):11. doi:10.1128/AAC.00776-2










